| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1007654750 |
| P356 | DOI | 10.1038/LEU.2008.207 |
| P698 | PubMed publication ID | 18685611 |
| P5875 | ResearchGate publication ID | 23154548 |
| P50 | author | Massimo Libra | Q37842996 |
| James A. McCubrey | Q42317570 | ||
| Ferdinando Nicoletti | Q84521195 | ||
| P2093 | author name string | J Troppmair | |
| A M Martelli | |||
| F Nicoletti | |||
| M McMahon | |||
| C Evangelisti | |||
| E W T Wong | |||
| G Ligresti | |||
| J Bäsecke | |||
| L S Steelman | |||
| N Misaghian | |||
| S L Abrams | |||
| S Molton | |||
| P2860 | cites work | BOK and NOXA are essential mediators of p53-dependent apoptosis | Q24337595 |
| Clinical significance of TP53 mutation in myeloma | Q27851404 | ||
| Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia | Q28305210 | ||
| Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome | Q34360312 | ||
| p53 induction and activation of DDR1 kinase counteract p53-mediated apoptosis and influence p53 regulation through a positive feedback loop | Q34794097 | ||
| Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies | Q35817464 | ||
| MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy | Q35848425 | ||
| Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia | Q35849887 | ||
| ABC transporters in the balance: is there a role in multidrug resistance? | Q36018461 | ||
| New agents for the treatment of acute myeloid leukemia | Q36413300 | ||
| The role of p73 in hematological malignancies | Q36422865 | ||
| Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. | Q36461618 | ||
| Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities | Q36490192 | ||
| The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR). | Q36536579 | ||
| Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia | Q36600942 | ||
| Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma | Q36629205 | ||
| Signal transduction pathways that contribute to myeloid differentiation | Q36795284 | ||
| The hunt for cancer-initiating cells: a history stemming from leukemia | Q36836595 | ||
| Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside | Q36907296 | ||
| Genetics of therapy-related myelodysplasia and acute myeloid leukemia | Q37058777 | ||
| Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. | Q37109225 | ||
| Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. | Q37109227 | ||
| Sustained activation of Ras/Raf/mitogen-activated protein kinase cascade by the tumor suppressor p53. | Q37222088 | ||
| Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. | Q37331720 | ||
| Enrichment of hematopoietic precursor cells and cloning of multipotential B-lymphocyte precursors | Q37554117 | ||
| Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals | Q39458674 | ||
| MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2. | Q40013409 | ||
| Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. | Q40024347 | ||
| Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway | Q40117414 | ||
| Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. | Q40127987 | ||
| Synergistic effect of AS101 and Bryostatin-1 on myeloid leukemia cell differentiation in vitro and in an animal model | Q40131885 | ||
| Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells | Q40149315 | ||
| Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance. | Q40154931 | ||
| A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells. | Q40160733 | ||
| Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/Reed-Sternberg cells | Q40176347 | ||
| Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts | Q40184405 | ||
| p53 regulates ERK activation in carboplatin induced apoptosis in cervical carcinoma: a novel target of p53 in apoptosis. | Q40185793 | ||
| Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML. | Q40195272 | ||
| Discoidin domain receptor 1 receptor tyrosine kinase induces cyclooxygenase-2 and promotes chemoresistance through nuclear factor-kappaB pathway activation | Q40243292 | ||
| Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells. | Q40287051 | ||
| Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. | Q40490617 | ||
| Down-regulation of wild-type p53 activity interferes with apoptosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal. | Q40791236 | ||
| Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. | Q40845331 | ||
| Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells. | Q44419395 | ||
| The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism | Q46666883 | ||
| Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells | Q46956224 | ||
| Differential effects of retroviral long terminal repeats on interleukin-3 gene expression and autocrine transformation. | Q53440045 | ||
| The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. | Q53595110 | ||
| The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion | Q56995355 | ||
| Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated | Q60203798 | ||
| Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor progno | Q73567637 | ||
| Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice | Q79235569 | ||
| Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine | Q80413377 | ||
| PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes | Q80599609 | ||
| Multiple forms of nuclear p53 formed in human Raji and MEC1 cells treated with fludarabine | Q80866763 | ||
| P433 | issue | 11 | |
| P921 | main subject | drug resistance | Q12147416 |
| P304 | page(s) | 2080-2090 | |
| P577 | publication date | 2008-08-07 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance | |
| P478 | volume | 22 |
| Q36963025 | Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis. |
| Q39191779 | Can systems biology approach help in finding more effective treatment for acute myeloid leukemia? |
| Q36524079 | Correlation between the overexpression of Yin Yang 1 and the expression levels of miRNAs in Burkitt's lymphoma: A computational study. |
| Q37192602 | Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs |
| Q49882954 | Drug-resistance in doxorubicin-resistant FL5.12 hematopoietic cells: elevated MDR1, drug efflux and side-population positive and decreased BCL2-family member expression |
| Q49588413 | Effect of basic fibroblast growth factor antibody combined with irinotecan on proliferation and apoptosis of small cell lung cancer H223 cells in vitro |
| Q37691441 | Emerging MEK inhibitors. |
| Q37192616 | Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy |
| Q43143677 | Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms |
| Q37406955 | Fluoro-edenite induces fibulin-3 overexpression in non-malignant human mesothelial cells |
| Q34810055 | Functional p53 is required for rapid restoration of daunorubicin-induced lesions of the spleen |
| Q38837564 | Identifying novel therapeutic agents using xenograft models of pediatric cancer |
| Q38402255 | Induction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanoma cells |
| Q36392660 | Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program |
| Q35556981 | Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells |
| Q38092584 | MEK inhibitors as a chemotherapeutic intervention in multiple myeloma |
| Q28079232 | Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies |
| Q47148711 | Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells |
| Q28393587 | Occupational exposure to carcinogens: Benzene, pesticides and fibers (Review) |
| Q30244123 | Occupational exposure to pesticides as a possible risk factor for the development of chronic diseases in humans (Review) |
| Q51747038 | Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia. |
| Q37433613 | Preparation of (-)-Nutlin-3 using enantioselective organocatalysis at decagram scale. |
| Q39143241 | Rapamycin interacts synergistically with idarubicin to induce T-leukemia cell apoptosis in vitro and in a mesenchymal stem cell simulated drug-resistant microenvironment via Akt/mammalian target of rapamycin and extracellular signal-related kinase s |
| Q38721721 | Revealing protein networks and gene-drug connectivity in cancer from direct information. |
| Q34966603 | Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging |
| Q37865381 | Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. |
| Q102389066 | Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms |
| Q33823577 | Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells. |
| Q47110143 | Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells |
| Q33493174 | Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia |
| Q37192611 | The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy |
| Q34024558 | The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. |
| Q54694835 | The role of TP53 and p21 gene polymorphisms in breast cancer biology in a well specified and characterized German cohort. |
| Q37837732 | Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. |
| Q64980569 | Transmembrane-4 L-six family member-1 (TM4SF1) promotes non-small cell lung cancer proliferation, invasion and chemo-resistance through regulating the DDR1/Akt/ERK-mTOR axis. |
| Q39840784 | Ubiquitin ligase Cbl-b sensitizes leukemia and gastric cancer cells to anthracyclines by activating the mitochondrial pathway and modulating Akt and ERK survival signals |
| Q39590174 | Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response. |
| Q41371230 | miR-202 Suppresses Cell Proliferation by Targeting FOXR2 in Endometrial Adenocarcinoma |
| Q39446317 | p53 modulates acquired resistance to EGFR inhibitors and radiation. |
Search more.